Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.
Dr. Lecia Sequist on Multiplex Next Generation Sequencing and its Effect on Molecular Oncology Practice
Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
Dr. Lecia Sequist: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Lecia Sequist of Massachusetts General Hospital offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years.
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.
In Me or Around Me? Genetics vs. Environment in Lung Cancer
HOST: Hildy Grossman, CO-HOST: Jordan Rich
GUESTS: Lecia Sequist, MD and Allison Chang, MD, Ph.D.
We are building on our previous "All in the Family" episode, with Jaclyn Lo Piccolo,
MD, Ph.D., Pasi Janne, MD, Ph.D., of the Dana Farber Cancer Institute and Jill
Feldman from EGFR Resister…
ASCO24: Transforming the Lung Cancer Treatment Landscape
Drs. Vamsi Velcheti and Nathan Pennell discuss novel approaches and key studies in lung cancer that were showcased at the 2024 ASCO Annual Meeting, including the Plenary abstracts LAURA and ADRIATIC.
TRANSCRIPT
Dr. Vamsi Velcheti: Hello, I am Dr. Vamsi Velcheti, your guest host for the ASCO …
موتور جستجوی پادکست
می توانید از وب سایت ما برای جستجوی پادکست های3,837,603و قسمت های197,901,203بر اساس افراد، مکان ها یا موضوعات استفاده کنید.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم